U.S. Electrotherapy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

U.S. Electrotherapy Market Trends and Insights

Chronic Pain Burden and Aging-Related Pain Incidence

Chronic pain remains a significant driver for the United States electrotherapy market, with 24.3% of adults, approximately 60 million people, experiencing chronic pain in 2025. Among them, 8.9% faced high-impact chronic pain that disrupted daily activities. Older adults were most affected, with a 36.0% prevalence among those aged 65 and above, compared to 12.3% to 28.7% in younger groups.^{[2] Springer Nature, “Current Pain and Headache Reports Article on Peripheral Nerve Stimulation,” Current Pain and Headache Reports, springer.com} Conditions like osteoarthritis and spinal degeneration highlight the role of electrotherapy in drug-sparing pain management. The market benefits from a stable demand base across outpatient rehabilitation, homecare, and chronic disease management settings.

Opioid-Sparing Treatment Preference Across Pain Care Pathways

The shift toward non-opioid pain treatments is strengthening the United States electrotherapy market across hospitals, outpatient facilities, and specialist channels. The NOPAIN Act supports Medicare payments for non-opioid treatments through 2027, enhancing the financial case for device-based pain management. The Alternatives to PAIN Act reduces prior authorization barriers under Medicare Part D, favoring non-drug therapies.^{[3]Centers for Medicare & Medicaid Services, “Transcutaneous Electrical Nerve Stimulators, LCD L33802,” Medicare Coverage Database, cms.gov} Specialist endorsements for peripheral nerve stimulation in chronic back pain further drive adoption, with higher-value prescription systems gaining traction over consumer devices.

Home-Based Rehabilitation and Portable Device Adoption

Home-based treatments are expanding the United States electrotherapy market by increasing accessibility. ONWARD Medical received FDA clearance in 2025 for ARC-EX home use in incomplete spinal cord injury patients, with over 60 clinics adopting the system. ANEUVO's ExaStim, cleared in 2026, supports spinal cord injury care, including home use. Beurer expanded its TENS, EMS, and heat therapy portfolio in 2026, targeting drug-free pain relief outside clinical settings. These advancements bridge supervised rehabilitation and self-administered therapy, enhancing payer confidence with improved safety and regulatory standards.

Higher Outpatient Musculoskeletal and Post-Surgical Rehab Volume

The shift of musculoskeletal care to outpatient settings is driving demand for electrotherapy devices in the United States. Procedure migration to ambulatory and outpatient environments has increased the relevance of devices in discharge planning and recovery. Federal payment reforms tied to non-opioid treatments further support this trend. Devices like TENS, NMES, and interferential therapy are integral to post-operative rehabilitation, particularly after joint replacements and spinal procedures. A 2026 fibromyalgia study involving 384 patients across 28 clinics also validated TENS use in non-surgical populations, positioning rehabilitation providers as key influencers in patient adoption.

Reimbursement Friction, Prior Authorization, and LCD Limits

Reimbursement complexities remain a key short-term challenge for the United States electrotherapy market. The WISeR Model, effective January 1, 2026, in states like Arizona, New Jersey, and Texas, introduces AI-assisted prior authorization for electrical nerve stimulators, increasing operational burdens and extending sales cycles. Stricter compliance requirements, such as the CMS LCD L33802 for TENS implemented in January 2024, have already added to suppliers' challenges. Larger manufacturers manage these changes more effectively due to scale and resources, while smaller suppliers face significant administrative hurdles. Texas, a critical Medicare-heavy market, amplifies the revenue impact of these added reviews.

Mixed Clinical Evidence Across Some Indications and Modalities

Uneven clinical evidence across surface electrotherapy modalities limits market growth in specific indications. Conventional TENS shows inconsistent results for chronic low back pain and knee osteoarthritis, while microcurrent and interferential therapies face similar challenges due to limited high-level evidence and payer scrutiny. A March 2026 fibromyalgia study demonstrated the value of larger pragmatic trials in generating real-world support. Implantable neuromodulation benefits from stronger evidence and specialist guidelines, creating a market divide where premium implantables maintain value through evidence, while surface devices compete on price, access, and convenience.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapy Type: TENS Leads Volume as NMES Reshapes the Growth Profile

In 2025, TENS therapy devices held a 32.55% share of the therapy type mix, leading the United States electrotherapy market. Their dominance was driven by broad availability across prescription and over-the-counter channels, enhancing access through clinics, pharmacies, retail outlets, and direct purchases. The FDA's 510(k) pathway remained active, with clearances like the OTC 4-Channel Rechargeable TENS Unit and Zynex Medical's TensWave expanding the prescription TENS portfolio. Interferential and microcurrent therapies retained their roles in physiotherapy, while PENS and bone growth stimulation remained specialized.

Neuromuscular electrical stimulation (NMES) is projected to grow at a 6.80% CAGR through 2031, making it the fastest-growing therapy type. Its adoption is increasing in stroke rehabilitation, spinal cord injury recovery, and post-surgical muscle re-education, supported by home-use clearances. High-value implantables like spinal cord stimulation and sacral neuromodulation continue to dominate revenue, while surface devices drive higher unit sales.

By Application: Pain Management Dominates, Neuromuscular Rehabilitation Accelerates

Pain management accounted for 42.88% of the application mix in 2025, leading the United States electrotherapy market. This reflects the concentration of prescription TENS, peripheral nerve stimulation, and spinal cord stimulation in outpatient pain clinics and spine practices. Bone healing and spinal fusion support maintained stable demand, driven by clinical necessity in high-risk cases, while wound care and dermatological applications remained limited due to reimbursement challenges.

The market for neuromuscular dysfunction and rehabilitation is forecast to grow at a 6.35% CAGR through 2031, driven by rising incidences of stroke, spinal cord injuries, and traumatic brain injuries. Boston Scientific's acquisition of Axonics strengthened its position in pelvic dysfunction therapy, adding a high-growth segment to the application mix. Pain management remains the anchor, while rehabilitation and pelvic neuromodulation are gaining traction.

By End User: Hospital Primacy Persists While Homecare Redefines the Margin Profile

Hospitals and health systems captured 48.35% of end-user revenue in 2025, maintaining their lead in the United States electrotherapy market. Their dominance is tied to implantable neuromodulation procedures requiring surgical infrastructure and post-implant monitoring. Pain management and spine clinics remain key for non-implantable devices, while ambulatory surgery centers are gaining relevance as orthopedic and spine procedures shift from inpatient care.

The homecare segment is expected to grow at a 7.10% CAGR through 2031, making it the fastest-growing end-user category. Clearances for clinical-grade neurostimulation devices have expanded home use, reducing reliance on in-clinic visits. Zynex's restructuring and improved reimbursement access highlight the potential of direct-to-home models, positioning homecare as a significant commercial channel.

By Prescription Type: Prescription Segment Retains Value Share as OTC Grows in Volume

In 2025, prescription devices accounted for 79.25% of revenue, underscoring their dominance in the United States electrotherapy market. High-value products like spinal cord stimulation and sacral neuromodulation remain firmly within this channel, supported by stringent coverage criteria and clinical oversight. Hybrid direct-to-home models are emerging around the prescription base, ensuring its continued revenue leadership.

Over-the-counter devices are projected to grow at a 6.90% CAGR through 2031, driven by easier consumer access, increased awareness of drug-free pain relief, and digital discovery of home-use options. While OTC devices are expanding in volume, their value growth is limited by lower selling prices and intense competition. The prescription channel is expected to retain its dominant revenue share as OTC devices expand their market presence.

Geography Analysis

The United States electrotherapy market benefits from high healthcare spending, established reimbursement channels for durable medical equipment, and an FDA framework supporting implantable and surface stimulation technologies. Demand varies due to differences in chronic pain prevalence by urbanization and gender. In large metropolitan areas, 22.2% of women and 18.8% of men reported chronic pain in the past three months, while rural and micropolitan areas showed higher rates. 

The Sun Belt is the leading commercial region for the United States electrotherapy market, driven by large older populations and extensive networks of pain clinics, hospitals, and ambulatory surgery centers in states like Texas, Florida, Arizona, and California. Texas and Arizona's participation in the WISeR pilot from January 2026 adds compliance requirements for suppliers with significant Medicare exposure. 

The Midwest and Mid-Atlantic regions exhibit unique demand patterns, with the Veterans Health Administration's extensive network of over 170 medical centers providing centralized procurement for prescription electrotherapy devices. Strong physical therapy utilization in parts of the Midwest drives recurring demand for clinical-grade TENS and NMES systems in rehabilitation.